Debt-to-equity of Aspire Biopharma Holdings, Inc. from 30 Sep 2022 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aspire Biopharma Holdings, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2022 to 30 Sep 2025.
  • Aspire Biopharma Holdings, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was -118%, a 83% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Aspire Biopharma Holdings, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 -118% +568% +83% 30 Sep 2025
Q2 2025 -145% +455% +76% 30 Jun 2025
Q1 2025 -226% +241% +52% 31 Mar 2025
Q4 2024 -510% -394% -342% 31 Dec 2024
Q3 2024 -686% -572% -500% 30 Sep 2024
Q2 2024 -600% -487% -428% 30 Jun 2024
Q1 2024 -467% -354% -314% 31 Mar 2024
Q4 2023 -115% +0.33% +0.28% 31 Dec 2023
Q3 2023 -114% +3.7% +3.1% 30 Sep 2023
Q2 2023 -114% 30 Jun 2023
Q1 2023 -113% 31 Mar 2023
Q4 2022 -116% 31 Dec 2022
Q3 2022 -118% 30 Sep 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.